This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameEpofolate
Accession NumberDB12266
TypeSmall Molecule
GroupsInvestigational
Description

Epofolate has been used in trials studying the treatment of Advanced Solid Tumors.

Structure
Thumb
Synonyms
BMS-753493
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIQ3XAW4B1DP
CAS number958646-17-8
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Epofolate.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Epofolate.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epofolate.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Epofolate.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Epofolate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Epofolate.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Epofolate.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epofolate.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Epofolate.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Epofolate.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epofolate.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Epofolate.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2TerminatedTreatmentAdvanced Solid Tumors2
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified
Drug created on October 20, 2016 15:46 / Updated on June 28, 2017 10:03